The U.S. Food and Drug Administration (FDA) has officially approved a new lung cancer drug, Jideytro (zidesamtinib), by pharmaceutical giant GSK. This FDA approval for GSK’s lung cancer drug Jideytro was made possible with the recently completed $10.6 billion Nuvalent acquisition, bringing a next-generation targeted therapy to the GSK oncology pipeline.
The Jideytro lung cancer drug provides a treatment option for adult patients living with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 kinase inhibitor. Significantly, this Jideytro FDA approval is GSK’s first-ever approved medicine for lung cancer. The green light arrived well ahead of the FDA’s original September 18, 2026, target action date.
About the FDA-Approved GSK’s Jideytro Drug
Jideytro lung cancer drug stands out as a next-generation non-small cell lung cancer treatment. This major milestone in ROS1-positive NSCLC treatment specifically helps adult patients whose cancer has progressed after initial targeted therapies.
Jideytro was deliberately designed to target ROS1 resistance mutations while selectively sparing the TRK protein family. Sparing TRK helps reduce off-target toxicities that often limit a patient’s ability to stay on medication long-term.
Additionally, Jideytro crosses the blood-brain barrier effectively to treat central nervous system (CNS) metastases. This allows the drug to challenge established market competitors like Pfizer’s Xalkori, Roche’s Rozlytrek, Bristol Myers Squibb’s Augtyro, and Nuvation Bio’s Ibtrozi.
According to estimates from GSK, approximately 50,000 new cases of ROS1-positive NSCLC are diagnosed each year globally. Many of these individuals are non-smokers in their 40s or 50s. Because cancer cells often adapt to early interventions, there is a critical unmet need for effective next-generation therapies once early treatments stop working.
Clinical Trial Results Behind Jideytro FDA Approval
The FDA approval for GSK’s lung cancer drug was based on compelling efficacy data from 117 patients enrolled in the global ARROS-1 Phase I/II clinical trial (NCT05118789). These 117 heavily pre-treated individuals received a 100 mg daily oral dose of Jideytro lung cancer drug, demonstrating meaningful clinical outcomes:
- Overall Response Rate (ORR): Achieved a 44% ORR across the total trial group.
- Durable Response: 82% of responding patients maintained their response at 6 months, while 69% remained in response at 12 months.
- Brain Metastases Impact: Recorded a 48% ORR in patients with measurable brain metastases, including a 22% complete response rate.
- Targeting Mutations: Delivered a 50% ORR in patients harboring specific ROS1 resistance mutations.
These data points demonstrate that GSK’s Jideytro drug can re-establish disease control even after earlier treatments have failed.
“Despite advances in treatment, resistance mutations, disease progression in the brain and treatment-related adverse events continue to create challenges for patients,” noted Dr. Alexander Drilon, ARROS-1 trial investigator at Memorial Sloan Kettering Cancer Center. “The responses observed in ARROS-1, including in heavily pre-treated patients, represent meaningful progress for people living with this disease.”
Safety Considerations For Jideytro Lung Cancer Drug
Though FDA approval for GSK’s lung cancer drug Jideytro has been granted, it carries specific safety considerations. The most common adverse reactions reported in clinical trials include:
- Edema (swelling)
- Peripheral neuropathy (nerve tingling or pain)
Risks of Jideytro drug highlighted in prescribing warnings:
- CNS adverse reactions
- QTc interval prolongation
- interstitial lung disease
- skeletal fractures
- pancreatic toxicity
- and embryo-fetal toxicity
Jideytro is taken as a 100 mg oral tablet once daily until disease progression or unmanageable toxicity occurs.
GSK’s Nuvalent Acquisition Leads to Jideytro FDA Approval
The FDA approval for GSK’s lung cancer drug serves as the first commercial success originating from the company’s recent $ 10.6 billion Nuvalent acquisition. This regulatory win accelerates the company’s broader effort to expand its footprint in solid tumors beyond blood and women’s health. Indeed, GSK continues evaluating innovative approaches, as seen with trials like the Jemperli cancer drug trial.
Additionally, the GSK oncology pipeline is expanding. Key upcoming developments include:
- Neladalkib (NVL-655): An ALK-positive NSCLC therapy with an FDA decision date targeted for November 27, 2026.
- NVL-330: An investigational candidate designed for HER2-altered NSCLC.
- Risvutatug rezetecan (Ris-Rez): A promising candidate currently in late-stage development for extensive-stage small-cell lung cancer.
Future of GSK’s Lung Cancer Drug
Securing FDA approval for GSK’s lung cancer drug officially brings the global pharmaceutical giant into the highly competitive lung cancer market. Backed by strong clinical response rates in brain metastases and resistance mutations, Jideytro offers new hope when previous therapies fail. GSK executive leadership has noted that Jideytro holds multi-blockbuster potential.
Although the current Jideytro FDA approval covers second-line treatment, GSK intends to pursue a first-line label expansion. Early clinical investigations also suggest Jideytro could display broad activity across other ROS1-positive solid tumor types.
As GSK advances its growing pipeline, this approval establishes a strong foundation for future first-line oncology treatments.
Sanskruti Jadhav
